CARIS LIFE SCIENCES INC (CAI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CAI • US1421521071

21.5 USD
-0.67 (-3.02%)
At close: Feb 11, 2026
21.5 USD
0 (0%)
After Hours: 2/11/2026, 8:09:45 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall CAI gets a fundamental rating of 3 out of 10. We evaluated CAI against 523 industry peers in the Biotechnology industry. The financial health of CAI is average, but there are quite some concerns on its profitability. CAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CAI had negative earnings in the past year.
CAI Yearly Net Income VS EBIT VS OCF VS FCFCAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

  • CAI's Return On Assets of -101.38% is on the low side compared to the rest of the industry. CAI is outperformed by 75.14% of its industry peers.
  • The Return On Equity of CAI (-208.66%) is worse than 68.83% of its industry peers.
Industry RankSector Rank
ROA -101.38%
ROE -208.66%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CAI Yearly ROA, ROE, ROICCAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • CAI has a Gross Margin of 53.54%. This is in the better half of the industry: CAI outperforms 76.29% of its industry peers.
  • The Profit Margin and Operating Margin are not available for CAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAI Yearly Profit, Operating, Gross MarginsCAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CAI has about the same amount of shares outstanding.
  • Compared to 5 years ago, CAI has more shares outstanding
  • The debt/assets ratio for CAI is higher compared to a year ago.
CAI Yearly Shares OutstandingCAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2023 2024 50M 100M 150M 200M 250M
CAI Yearly Total Debt VS Total AssetsCAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2023 2024 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 4.32 indicates that CAI is not in any danger for bankruptcy at the moment.
  • CAI's Altman-Z score of 4.32 is fine compared to the rest of the industry. CAI outperforms 71.70% of its industry peers.
  • A Debt/Equity ratio of 0.79 indicates that CAI is somewhat dependend on debt financing.
  • CAI's Debt to Equity ratio of 0.79 is on the low side compared to the rest of the industry. CAI is outperformed by 72.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 4.32
ROIC/WACCN/A
WACC12.73%
CAI Yearly LT Debt VS Equity VS FCFCAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 9.93 indicates that CAI has no problem at all paying its short term obligations.
  • The Current ratio of CAI (9.93) is better than 81.07% of its industry peers.
  • A Quick Ratio of 9.36 indicates that CAI has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 9.36, CAI is doing good in the industry, outperforming 79.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.93
Quick Ratio 9.36
CAI Yearly Current Assets VS Current LiabilitesCAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
  • CAI shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.67%.
  • The Revenue has been growing slightly by 6.64% on average over the past years.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -37.72% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 30.63% on average over the next years. This is a very strong growth
EPS Next Y-131.19%
EPS Next 2Y-83.62%
EPS Next 3Y-58.31%
EPS Next 5Y-37.72%
Revenue Next Year80.21%
Revenue Next 2Y55.09%
Revenue Next 3Y43.23%
Revenue Next 5Y30.63%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CAI Yearly Revenue VS EstimatesCAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
CAI Yearly EPS VS EstimatesCAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 114.45, CAI can be considered very expensive at the moment.
  • 87.76% of the companies in the same industry are more expensive than CAI, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of CAI to the average of the S&P500 Index (28.01), we can say CAI is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 114.45
CAI Price Earnings VS Forward Price EarningsCAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAI Per share dataCAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • CAI's earnings are expected to decrease with -58.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.62%
EPS Next 3Y-58.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CARIS LIFE SCIENCES INC

NASDAQ:CAI (2/11/2026, 8:09:45 PM)

After market: 21.5 0 (0%)

21.5

-0.67 (-3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)N/A
Inst Owners37.15%
Inst Owner Change1.91%
Ins Owners48.47%
Ins Owner Change-1.33%
Market Cap6.07B
Revenue(TTM)931.41M
Net Income(TTM)-998.17M
Analysts84.62
Price Target38.65 (79.77%)
Short Float %5.68%
Short Ratio2.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1853.44%
Min EPS beat(2)-3845.54%
Max EPS beat(2)138.66%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)28.77%
Min Revenue beat(2)26.17%
Max Revenue beat(2)31.38%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.59%
PT rev (3m)-3.16%
EPS NQ rev (1m)98.1%
EPS NQ rev (3m)98.65%
EPS NY rev (1m)4.23%
EPS NY rev (3m)14.45%
Revenue NQ rev (1m)4.63%
Revenue NQ rev (3m)5.49%
Revenue NY rev (1m)2.31%
Revenue NY rev (3m)10.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 114.45
P/S 6.51
P/FCF N/A
P/OCF N/A
P/B 12.68
P/tB 13.22
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)0.19
Fwd EY0.87%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.3
BVpS1.7
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.38%
ROE -208.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.93
Quick Ratio 9.36
Altman-Z 4.32
F-ScoreN/A
WACC12.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-131.19%
EPS Next 2Y-83.62%
EPS Next 3Y-58.31%
EPS Next 5Y-37.72%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year80.21%
Revenue Next 2Y55.09%
Revenue Next 3Y43.23%
Revenue Next 5Y30.63%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.54%
EBIT Next 3Y47.53%
EBIT Next 5Y29.85%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A

CARIS LIFE SCIENCES INC / CAI FAQ

What is the fundamental rating for CAI stock?

ChartMill assigns a fundamental rating of 3 / 10 to CAI.


Can you provide the valuation status for CARIS LIFE SCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Overvalued.


Can you provide the profitability details for CARIS LIFE SCIENCES INC?

CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CAI stock?

The Earnings per Share (EPS) of CARIS LIFE SCIENCES INC (CAI) is expected to decline by -131.19% in the next year.